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A consensus meeting on autoimmune pancreatitis 
(AIP) was held in Seoul on August 31, 2007. Many 
Korean and Japanese gastroenterologist interested in 
AIP participated in the joint symposium, and issues 
related to histology, radiology, clinical manifestation, 
serology, and diagnostic criteria were discussed. This 
joint meeting indicated the need for unified diagnostic 
criterion for AIP in Korea and Japan. Here, we pro-
vide a summary of the symposium presentations and 
discussions. (Gut and Liver 2008;2:81-87)
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INTRODUCTION
Speaker: Jae Bock Chung
  A concept of autoimmune pancreatitis (AIP) was pro-
posed firstly by Japanese investigators in 1995. Thereafter 
many AIP cases have been reported mostly from Japan 
and Korea. We are now familiar with radiologic findings, 
biochemical markers, clinical manifestations, histologic 
findings, and extrapancreatic lesions of AIP. And also we 
know that steroid therapy is effective for AIP.
  However, we still do not know the cause, actual patho-
genesis, natural course and long term prognosis of AIP at 
present. There are several diagnostic criteria of AIP re-
ported from Japan, Korea, and Western countries.1-3 
However, there are some limitations of each criterion to 
satisfy every case of AIP and controversial point about the 
response to steroid therapy including as a diagnostic 
criteria. 
  Today we will discuss about the characteristic features 
of AIP, and will compare the diagnostic criteria for AIP of 
Japan, USA and Korea, and finally we will discuss about 
the ideal diagnostic criteria for AIP to make Asian 
criteria. 
  It is not easy to make ideal diagnostic criteria for AIP 
by today's symposium within six hours. But I believe and 
hope that all the participants and speakers can make the 
ideal diagnostic criteria for AIP by active discussion at the 
end of this symposium.
PRESENTATIONS
1. Imaging findings of AIP
Speaker: Jae Hoon Lim
  Imaging findings of AIP are fairly characteristic.4,5 In an 
appropriate clinical setting, a constellation of imaging fea-
tures is very helpful in the diagnosis of AIP. The abnor-
mal findings are reversible with steroid therapy and thus 
imaging can be used as an evaluation of treatment res-
ponse.
  The typical findings of computed tomography (CT) are 
diffuse enlargement of the entire pancreas with homoge-
nous texture. The normal tiny cysts or serration along the 
pancreatic duct is lost and becomes smooth. The enlarged 
pancreas is covered by a thin, low density rim and the 
surface is pencil sharp. In some patients, there may be 
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peripancreatic stranding and thickening of renal fascia. 
Frequently, the involved lesion may be focal or segmental, 
and the involved segment may be enlarged mimicking a 
pancreatic mass. Usually, there is no calcification, peri-
pancreatic fluid collection or vascular involvement.
  Ultrasonography shows diffuse homogenous enlarge-
ment of the pancreas. Magnetic resonance imaging (MRI) 
also reveals diffuse enlargement with rim enhancement. 
Magnetic resonance cholangiopancreaticography (MRCP) 
reveals diffuse narrowing and minute ductal irregularity 
along the main pancreatic duct. Sometimes, there may be 
a focal stricture. Endoscopic retrograde cholangiopancrea-
ticography (ERCP) shows characteristic diffuse narrowing 
with irregularity or serration along varying segment of the 
main pancreatic duct. Focal stricture may be present. The 
intrapancreatic segment of the common bile duct may be 
focally or segmentally narrowed resulting in dilation of 
the proximal bile ducts. Infrequently the proximal extra-
hepatic ducts or intrahepatic bile ducts may be involved 
resulting in various degree of narrowing. By administrat-
ing steroid therapy, those abnormal findings resolve soon 
and become completely normal.
2. AIP: Serology
Speaker: Shigeyuki Kawa and Hideaki Hamano
  Various serum markers in AIP are associated with diag-
nosis, disease activity and pathogenesis. The utility of 
IgG4 for the diagnosis of AIP has been accepted world-
wide. Sensitivity is variable from 73% to 92%,6-8 and the 
difference in sensitivity is partly due to the differences of 
diagnostic criteria applied by individual countries. Sensi-
tivities for antinuclear antibody and rheumatoid factor 
were 60% and 20%.9 However, SS-A and SS-B, and an-
ti-mitochondrial antibody were scarcely found in sera of 
AIP patients. We investigated the outcome of long-term 
follow up of 51 patients with AIP, and found 21 patients 
(41%) with recurrences. Serum immune complex levels at 
onset were significantly higher in recurrence group than 
non-recurrence group. If the levels of immune complex at 
onset are over 10 g/dL, probability for recurrence is 60%. 
AIP is complicated with various extra-pancreatic involve-
ments. Serum IgG4 level was well correlated with the 
number of extra-pancreatic involvements, and lachrymal 
and salivary gland lesions and hilar lymphadenopathy are 
significantly associated with high serum levels of IgG4 
and immune complex. Decreased serum levels of C3 and 
C4 were found in 35% and 37% of AIP patients at on-
set,10 indicating that complement activation system is op-
erating in the pathogenesis of this disease. Elevated se-
rum levels of immune complex determined by C1q assay 
were significantly related to increased serum levels of 
IgG1 and decreased levels of C4, with a tendency toward 
decreased levels of C3, indicating that classical pathway 
may be operating in the pathogenesis of AIP.
3. AIP: Histology and immunostaining
Speaker: Se Jin Jang
  AIP is a newly established entity defined by the follow-
ing 3 characteristic clinicopathologic findings: (i) radio-
logic features of irregular narrowing of the main pancre-
atic duct and diffuse enlargement of the pancreas, (ii) lab-
oratory findings such as elevation of serum IgG or the 
presence of autoantibodies, and (iii) histopathologic features 
of lymphoplasmacytic sclerosing pancreatitis (LPSP).3,11 
Among them, histologic findings are generally known to 
be gold standard for the diagnosis of the disease. Howev-
er, since histologic components of normal pancreas in-
cluding acini, islets, ducts, blood vessels and connective 
tissue stroma respond to inflammatory stimuli with lim-
ited patterns, histologic features of AIP may overlap with 
other causes of chronic pancreatitis. Furthermore, as the 
chronic pancreatitis presents as repeated bouts of acute 
pancreatitis, the time of histologic examination during the 
disease process is another important variable to evaluate 
the histologic features.
  Acinar changes in AIP are characterized by loss of exo-
crine cells with lymphoplasmacytic infiltration and re-
placement by loose collagenous stroma (intralobular fib-
rosis). Atrophy of the islets is less prominent. Some-
times, lobular architectures are preserved even though 
there are complete losses of acini. Ductal changes are 
most characteristic features of AIP. Intense lympho-
plasmacytic infiltration in and around the wall of main 
pancreatic and medium-sized interlobular ducts with scle-
rosis and luminal narrowing, which has been named as 
LPSP, is considered as a histologic hallmark of AIP.12 
Sometimes, active chronic inflammation, characterized by 
granulocytic infiltration in the ductal epithelium without 
denudation (granulocytic epithelial lesion, GEL) can be 
seen. Although the inflammatory reaction is intense, tis-
sue necrosis by autodigestion is usually absent. Changes 
of blood vessels always appear in the intralobular small 
venules and interlobular veins. Perivenular lymphoplasma-
cytic infiltration with luminal obstruction forming an ob-
literative phlebitis is considered as a characteristic 
feature. Arteries and arterioles are always preserved. 
Those pathologic features are variable according to se-
verity of the disease or stage of the disease. Therefore, 
sometimes immunostainings are helpful. Demonstration 
of high density IgG4 positive cells by immunostaining is 
most widely accepted as typical finding of AIP. Charac-
teristic lobular changes, intralobular fibrosis with rela-
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tively preserved reticulin frameworks, can be visualized by 
immunostaining of collagen type IV. To distinguish from 
lymphoproliferative disorders, demonstration of polyclonal 
nature by immunostaining of CD3, CD20, CD4, and CD8 
will be helpful. In summary, LPSP with high density (20 
＞HPF) IgG4 positive cells and sclerosis with preserved 
lobular feature are diagnostic features of AIP.
4. Other organ involvement in AIP
Speaker: Tetsuhide Ito 
  The accumulation of clinical data in AIP patients has 
revealed a variety of extra-pancreatic involvement, includ-
ing sclerosing cholangitis, lacrimal and salivary gland 
swelling, hypothyroidism, hilar lymphadenopathy, retro-
peritoneal fibrosis, interstitial pneumonia, and interstitial 
nephritis.12-14 Most patients with AIP and sclerosing siala-
denitis show negativity for both anti-SSA and snti-SSB 
antibodies, suggesting that AIP differs from Sjogren's 
syndrome. Sclerosing cholangitis-like lesions accompany-
ing AIP and primary sclerosing cholangitis respond differ-
ently to steroid therapy and have different prognosis, sug-
gesting that they are not the same disorder. In this paper, 
we reported the result of incidence of extra-pancreatic in-
volvement based on 191 AIP patients collected from sev-
en institutions in Japan. The most frequent extra-pancreatic 
lesions in Japan were sclerosing cholangitis (58.6%), fol-
lowed by hilar lymphadenopathy (28.3%) and salivary 
gland lesion (24.6%). The frequency of other organ in-
volvement was as follows; retroperitoneal fibrosis in 
11.0%, chronic thyroiditis in 8.9%, pseudotumor of the 
lachrymal gland in 8.4%, interstitial nephritis in 3.7%, in-
terstitial pneumonia in 1.6%, thrombocytopenic purpura 
in 0.5%, and prostatitis in 0.5%. Interestingly, the compli-
cation of inflammatory bowel disease was 0%. Extra-pan-
creatic lesions have a characteristic histological finding of 
abundant IgG4-bearing plasma cell infiltration, and re-
spond favorably to steroid therapy.14 Diagnosing AIP is 
needed to distinguish it from pancreatic or biliary cancer. 
Furthermore, extra-pancreatic lesions with AIP should be 
carefully diagnosed to avoid inadequate steroid admini-
stration. The current concept of AIP including ex-
tra-pancreatic lesions and associated disorders suggests 
that AIP may be pancreatic manifestation of a systemic 
disorder. Recognition of these characteristic findings will 
help the correct diagnosis of this disease.
5. AIP: Response to steroid and recurrence
Speaker: Isao Nishimori, Masaru Koizumi, and Makoto Otsuki
  Most patients with AIP show a dramatic response to 
steroid therapy.7 To establish the standard therapeutic 
method for AIP, we set two rounds of survey asking 
treatment and clinical course of AIP patients in Japan.
  The first was the nation-wide survey for AIP patients, 
who fulfilled the Japanese AIP criteria 2002. Clinical re-
mission rate in patients treated with steroid (123/125; 
98.4%) was significantly higher than that in patients 
without steroid therapy (14/16; 87.5%) (p＜0.005). 
Among patients with steroid therapy, the initial does of 
predonisolone was 40 mg/day in 31 patients and 30 mg/ 
day in 54 patients (average: 0.6 mg/body weight kg/day). 
  The second survey was designed to ask therapeutic out-
come in AIP patients, who fulfilled the Japanese AIP cri-
teria 2006 and were clinically observed for at least 2 
years. Among 38 patients who showed clinical relapse, re-
lapse of pancreatic manifestations were seen in 19 patients 
(50.0%), extra-pancreatic manifestations in 11 (28.9%) 
and both in 8 (21.1%). The higher was the prednisolone- 
maintenance doses, the lower was the relapse rate. There 
was a significant difference in relapse rates between pa-
tients treated with 0-2.5 mg/day of prednisolone-main-
tenance dose (48.1%, n=52) and patients with 5.0-7.5 
mg/day (26.5%, n=34) (p＜0.05). In most patients, clin-
ical relapse appeared until 3 years after the start of ste-
roid therapy.
  In conclusion, steroid therapy with oral prednisolone is 
recommended for AIP patients; 0.6 mg/body weight 
kg/day of the starting dose and 5.0-7.5 mg/day of the 
maintenance dose for totally at least three years.
6. Overview of diagnostic criteria for AIP
Speaker: Ji Kon Ryu
  Although, Japan Pancreas Society proposed the diag-
nostic criteria for the first time in 2002,15 the diagnosis 
of AIP is still challenging. Recently, several other diag-
nostic criteria were proposed as followings: revised pro-
posal of JPS criteria 2006,1 HISORt criteria by Mayo 
Clinic,3 Kim’s criteria,2 Massachusetts General Hospital 
criteria.16 Therefore, the new diagnostic criteria made by 
worldwide consensus will lessen inter-observer variation 
and provide a strong base for the research. 
  Because AIP can mimic pancreatic cancer both clinically 
and radiologically, and because it is responsive to steroid 
therapy, the goal is to make a diagnosis before surgery to 
avoid unnecessary operation. The overall impact of a 
missed diagnosis of AIP is not trivial. In one large series, 
11 (2.5%) of 442 Whipple resections were for AIP; all 
were thought to be malignant preoperatively.17
  In 2005, Spainish group published their own diagnostic 
criteria using scoring system. The criteria included clinical 
manifestation, morphologic parameters, laboratory param-
eters (serum IgG and ANA) and definite diagnosis was 
made only by histopathologic findings.18 A total joint 
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score of 0 or 1 was considered ''probably not AIP'', 2 as 
''possible AIP'', and 3 as ''probable AIP''.
  In Korea, Kim et al proposed Kim’s criteria based on 
his experience in 28 patients with AIP at single center.2 
Kim`s criteria included pancreatic imaging, laboratory 
findings, histopathologic findings and responsiveness to 
steroid. In Japan, clinical diagnostic criteria of AIP were 
published as a revised proposal by the research commit-
tee of intractable disease of the pancreas supported by 
the Japan Pancreas Society.1 They focused on how to dis-
tinguish it from pancreatic or biliary cancer. The criteria 
contained three components the same as previous Japan 
criteria and some minor modifications were made. The 
Japanese criteria are based on the minimum consensus 
features of AIP to avoid the misdiagnosis of malignancy 
as much as possible, but not to pick up suspicious cases 
of AIP.
  The HISORt criteria were proposed by the Mayo clinic 
based on the 29 patients who met histologic criteria for 
AIP at single center.3 The criteria included 5 categories: 
histology, imaging, serology, other organ involvement and 
response to steroid therapy. The authors pointed out that 
the Japanese criteria for AIP focussed heavily on charac-
teristic pancreatic imaging and therefore lack sensitivity 
to diagnose the wide spectrum of manifestations of AIP. 
They insisted that HISORt criteria reflect the current un-
derstanding of AIP as a systemic steroid-responsive dis-
order characterized by tissue infiltration with IgG4-posi-
tive cells.
  Another new diagnostic criteria were proposed by Brugge 
at Massachusetts General Hospital (MGH).16 They defined 
AIP as a type of chronic pancreatitis characterized by an au-
toimmune inflammatory process in which prominent lym-
phocyte infiltration with associated fibrosis of the pancreas 
causes organ dysfunction. The MGH criteria are modified 
from those of the Japan Pancreas Society and minor mod-
ifications were done to elevate diagnostic sensitivity. They 
also suggested the diagnostic and treatment algorithm for 
AIP according to their diagnostic criteria. 
  In Korea, new Korean diagnostic criteria are established 
by the Korean Society of Pancreatobiliary Diseases and 
based on the Kim`s criteria including response to steroid 
therapy to improved the diagnostic sensitivity and 
specificity. Korean criteria considered the variety of imag-
ing findings of AIP and low yield of histologic acquisition. 
  Making a diagnosis of AIP can be challenging but is im-
portant to prevent unnecessary surgery. Diagnostic cri-
teria have been proposed to incorporate histologic, radio-
logic, serologic, and clinical information, including the 
presence of other associated diseases and response to ste-
roid therapy. Because the distinction between AIP and 
pancreatic cancer is difficult to make in many cases, every 
attempt needs to be made to exclude the possibility of 
malignancy, even if it results in a pancreatic resection for 
benign disease in some patients. As more data are gath-
ered on AIP across the world, the diagnostic criteria will 
be shifted.
7. Clinical diagnostic criteria of Japan compared 
with those of Korea and USA
Speaker: Kazuichi Okazaki 
  The concept of Japanese criteria-2006 is minimum con-
sensus for the practical use to differentiate AIP from pan-
creatic or biliary malignancy as far as possible, but nei-
ther for differentiation from systemic disorders or screen-
ing AIP. In Pancreatic imaging, typical pancreatogram 
with CT or MRI is required in Japanese,1 Korean2 and 
Mayo's Group-B criteria,3 but not in Mayo's G-C. ERCP is 
mandatory in the Japanese, but MRCP is also available in 
Korean and Mayo's. In the blood test, presence of auto-
antibody in addition to high serum IgG4 is available in 
the criteria of Korea and Japan, but not in Mayo's. 
Irrespective of laboratory or radiological data, only the 
LPSP is definitive for diagnosis of AIP in the Mayo's G-A, 
but not in Japan and Korea. In Mayo's and Korean cri-
teria, dense infiltration of IgG4 positive plasma cells in 
the pancreas specimen is useful for diagnosis when LPSP 
is not confirmed. Extra-pancreatic lesions are included in 
the Korean and Mayo, but not in Japanese criteria. 
Steroid trial for the pancreas and/or extra-pancreatic le-
sions is available in the Korean and Mayo's criteria, but 
not in Japanese criteria. We prospectively studied three 
criteria using 21 AIP cases in Kansai Medical University, 
in which the sensitivity of Japanese, Korean and Mayo' 
criteria was 71.4, 76.2, and 52.3%, respectively. Sensitivi-
ty of pancreas images (90-100%) and blood test (IgG; 
94%, IgG4; 81%, auto-Abs; 47%) are high, but low in 
histological findings from biopsied pancreatic specimen. 
These findings suggest that if steroid trial and presence of 
autoantibody are included in the criteria, diagnostic sensi-
tivity is increased. We experienced an 80 year-old male 
patient with AIP followed by pancreatic cancer 4 years 
later, which suggested pancreatic cancer may accompany 
with AIP. Although steroid trial may increase diagnostic 
sensitivity for AIP, efficacy of steroid should be carefully 
evaluated and facile therapeutic diagnosis is not recom-
mended at this moment.
8. Korean criteria: comparison with those of Japan 
and USA
Speaker: Kyutaek Lee
  The overwhelming majority of reports of AIP have 
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Table 1. Korean Criteria for Autoimmune Pancreatitis (2007)
Definite Diagnosis: Criterion I together with any of criterion II 
to IV
Criterion I. Imaging (Both required)
  1. Imaging (CT or MRI) of pancreatic parenchyma; Diffuse-
ly/segmentally/focally enlarged gland, occasionally with 
mass and/or hypoattenuation rim
  2. Imaging (ERCP or MRCP) of pancreaticobiliary ducts; 
Diffuse/segmental/focal pancreatic ductal narrowing, 
often with the stenosis of bile duct
Criterion II. Serology (One required)
  1. Elevated level of serum IgG or IgG4
  2. Detected autoantibodies
Criterion III. Histopathology of pancreatic/extrapancreatic 
Lesions (One required)
  1. Lymphoplasmacytic infiltration & fibrosis, often with 
obliterative phlebitis
  2. Presence of abundant (＞10 cells/HPF) IgG4-positive 
plasma cells
Criterion IV. Response to steroids
  1. Resolution/marked improvement of pancreatic/extrapan-
creatic lesion with steroid therapy
Probable Diagnosis: Criterion V or VI 
Criterion V.
  1. Unexplained pancreatic disease but only with charac-
teristic pancreatic histology
Criterion VI. (Both required)
  1. Other organ involvement and/or serologic abnormalities
  2. Various atypical pancreatic imaging suggesting chronic 
pancreatitis with negative workup for known etiologies
come from Asian countries (e.g. Japan and Korea), and 
the prevalence of AIP in Japan was estimated to be 0.82 
per 100,000.19-21 Therefore, it is reasonable to establish 
unified Asian diagnostic criteria.
  The revised Japanese criteria1 (2006) do not include the 
response to steroid therapy as a diagnostic component be-
cause inclusion of steroid responsiveness in the criteria 
may encourage the use of easy therapeutic diagnostic 
techniques just to distinguish AIP from pancreatic cancer. 
However, the new Korean criteria2 (2007) recommend 
short term (2 weeks) steroid trial to diagnosis AIP in 
suspicious cases with strict regulation. Two weeks delay 
of operation is not critical for the prognosis of pancreatic 
cancer patients. The American HISORt criteria3 (2006) 
was originally based on the histopathologic finding in-
stead of clinical and practical finding of Korean and Japan 
criteria. The histological diagnosis of LPSP has most com-
monly been made on specimens obtained by surgical 
resection. The criteria emphasizing the histological find-
ings of LPSP may have some limitations due to require-
ment of a large tissue sample. 
  Korean AIP criteria 2007 (Table 1) are aimed high sen-
sitivity to diagnose the wide spectrum of manifestations 
of AIP. 
  The diagnostic criteria for AIP are still evolving. 
Integrated diagnostic criteria are strongly advocated so 
that more patients can have an opportunity to receive 
medical treatment that will avoid any unnecessarily in-
vasive procedure.
9. Ideal diagnostic criteria for AIP
Speaker: Myung-Hwan Kim
  In theory, ideal diagnostic criteria should have 100% 
sensitivity and specificity; of course, such criteria do not 
exist in reality. Thus, the goal is to establish diagnostic 
criteria that have as high sensitivity as possible without 
sacrificing specificity. In practice, the differentiation of 
AIP from pancreatic cancer is the most important thing, 
so the high specificity of the criteria may have priority 
over high sensitivity. 
  When Japanese Pancreas Society published the diag-
nostic criterion of AIP for the first time in 2002,22 it was 
a criterion with emphasis on specificity. The strict crite-
rion that specified more than one third of entire main 
pancreatic duct should be involved along with enlarge-
ment of whole pancreas came from a concern that some 
pancreas cancer may be erroneously included. However, 
some have pointed out that the criteria are too stringent 
and sensitivity is sacrificed excessively. Therefore, in 
2006, Japan Pancreas Society has published the Revised 
Criteria. 
  On the other hand, Mayo clinic from US published a 
criteria3 (HISORt) in 2006 which has features that in-
clude diverse image presentation of AIP. This Criterion is 
notable for its more broad recognition of manifestation of 
AIP, but some consider specificity is sacrificed by includ-
ing atypical imagings such as atrophy, calcification and 
stones. We present the new Korean criteria, which has 
combined features of both Japan and US criteria and is 
intended to maximize sensitivity while not sacrificing 
specificity. 
  Diagnostic criteria for AIP are evolving. With accumu-
lation of clinical experience, development of newer diag-
nostic methods and change in disease concept, the criteria 
will need to be updated continuously. In this regard, con-
sensus needs to be reached for unified criteria that could 
be shared internationally throughout the world, and it is 
our hope that the new Korean criteria can contribute in 
establishment of such criteria in the future. 
10. Proposal of an Asian criteria for AIP
Speaker: Terumi Kamisawa
  It is of utmost importance that AIP be differentiated 
from pancreatic cancer. The Japanese diagnostic criteria of 
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Table 2. Asian Diagnostic Criteria for Autoimmune pan-
creatitis (Tentative)




Criterion IV. Response to steroids*
*Steroid should be given only to patients with a negative 
work-up for pancreatobiliary cancer. Facile diagnostic steroid 
trial should not be used.
AIP are based on minimum consensus features of AIP 
and aim to avoid misdiagnosis of malignancy. When re-
sponse to steroid therapy is added to the criteria, the di-
agnostic sensitivity is increased. In my recently experi-
enced 28 AIP cases, 6 seronegative cases could not be di-
agnosed in Japanese criteria, but they could be diagnosed 
by responsiveness to steroid therapy in Korean criteria. 
  However, the use of a steroid trial in cases where dif-
ferentiation from malignancy is an issue may result in de-
laying pancreatic cancer surgery, which could lead to can-
cer progression in several cases. Diagnostic trial of steroid 
therapy should be done carefully only by pancreatologists 
familiar to AIP. Since general physicians use the diag-
nostic criteria of AIP, diagnostic steroid trial should not 
be easily recommended in the criteria.
  I propose Asian diagnostic criteria of AIP (Table 2) and 
would stress that steroid should be given only to patients 
with a negative workup for pancreatobiliary cancer, and 
facile diagnostic steroid trial should not be used.
CONCLUSION
Speaker: Makoto Otsuki
  At present, there are four diagnostic criteria for AIP in-
cluding the Japanese, Korean, Mayo Clinic, and the Italian 
criteria. Diagnostic criteria should be simple enough for 
widespread use with ease, but stringent enough to avoid 
erroneous inclusion of malignant diseases as AIP. Diag-
nostic trial using short-term steroid harbors the risk of 
delaying diagnosis of pancreatic cancer and resulting in 
loss of chance for curative resection. Sometimes steroid 
can reduce the size of mass by suppressing inflammatory 
changes surrounding the pancreatic tumor. This is why 
Japanese gastroenterologists do not accept diagnostic trial 
of steroid. 
  It is not easy to making ideal diagnostic criteria fit for 
all cases of AIP and satisfying all gastroenterologists. It 
needs painstaking studies to further understand the dis-
ease entity both at the basic and clinical level. In this set-
ting, it is desirable to open a way for Japanese and 
Korean gastroenterologists to collaborate, communicate 
with, and work together to reach at common diagnostic 
criterion. Sharing diagnostic criteria will further enhance 
communication and give birth to synergistic effect on un-
derstanding the AIP. I believe that further studies in col-
laboration between Japan and Korea will dissolve many 
unsolved questions. I would like to close this second 
Japan-Korea symposium on AIP and express my thanks to 
all participants and those who organized this meeting. 
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